View : 666 Download: 0
Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
- Title
- Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
- Authors
- Bae, Soo Youn; Nam, Seok Jin; Jung, Yongsik; Lee, Sae Byul; Park, Byung-Woo; Lim, Woosung; Jung, Sung Hoo; Yang, Hsien Wen; Jung, Seung Pil
- Ewha Authors
- 임우성
- SCOPUS Author ID
- 임우성
- Issue Date
- 2018
- Journal Title
- BREAST CANCER RESEARCH AND TREATMENT
- ISSN
- 0167-6806
1573-7217
- Citation
- BREAST CANCER RESEARCH AND TREATMENT vol. 172, no. 2, pp. 437 - 444
- Keywords
- Triple-negative breast cancer; Chemotherapy; Prognosis; P53; Immunohistochemistry
- Publisher
- SPRINGER
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- PurposeTP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC.MethodsA total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 p53-positive (+) TNBC' patients and 5062 p53-negative (-) TNBC' patients.ResultsIn univariate analysis, p53(+) TNBC had a worse prognosis than p53(-) TNBC in patients not receiving chemotherapy (P=0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(-) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(-) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(-) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(-) TNBC, there was no risk reduction effect by chemotherapy.ConclusionThe prognosis of p53(+) TNBC has worse than p53(-) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(-) TNBC.
- DOI
- 10.1007/s10549-018-4928-2
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML